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Survivorship is a trait characterized by endurance and virility in the face of hardship. It
is largely considered a psychosocial attribute developed during fatal conditions, rather
than a biological trait for robustness in the context of complex, age-dependent diseases
like coronary artery disease (CAD). The purpose of this paper is to present the novel
phenotype, survivorship in CAD as an observed survival advantage concurrent with
clinically significant CAD.We present a model for characterizing survivorship in CAD and its
relationships with overlapping time- and clinically-related phenotypes. We offer an optimal
measurement interval for investigating survivorship in CAD. We hypothesize genetic
contributions to this construct and review the literature for evidence of genetic contribution
to overlapping phenotypes in support of our hypothesis. We also present preliminary
evidence of genetic effects on survival in people with clinically significant CAD from a
primary case-control study of symptomatic coronary disease. Identifying gene variants
that confer improved survival in the context of clinically appreciable CAD may improve
our understanding of cardioprotective mechanisms acting at the gene level and potentially
impact patients clinically in the future. Further, characterizing other survival-variant genetic
effects may improve signal-to-noise ratio in detecting gene associations for CAD.
Keywords: survivorship, survival, novel phenotype, coronary artery disease, atherosclerosis, LSAMP gene,
cardioprotection
“Old age is not a disease – it is strength and survivorship, triumph
over all kinds of vicissitudes and disappointments, trials and
illnesses.”
– Maggie Kuhn
INTRODUCTION
Survivorship is a unique clinical construct that can be character-
ized by the intersection of temporal factors related to lifespan,
disease-related burden and treatment, and mortality. The term
survivorship connotes traits or conditions of maintaining sur-
vival, whereas survival characterizes the state of living. Coronary
disease continues to be a leading cause of death in the U. S. and
a significant source of rising disease burden (Roger et al., 2012),
despite a decline in cardiovascular disease-related mortality in
past decades as a result of improved knowledge of risk factors and
biomarkers, and advances in pharmacotherapeutics and coronary
interventions (McGovern et al., 2001). Moreover, clinical predic-
tion of survival likelihood in the setting of coronary artery disease
(CAD) is inaccurate and difficult. Given recent advances in the
identification of cardioprotective gene variants, biological mark-
ers may provide critical insight into the conditions that support
survival in the context of CAD, or, what we term, survivorship in
CAD. The purpose of this paper is to introduce and define a novel
phenotype, “survivorship in CAD,” to provide a review of the lit-
erature, to present hypotheses for genetic contributions, and to
present preliminary evidence of survival-variant genes unique to
CAD.
SURVIVAL vs. SURVIVORSHIP
The concept of survivorship has many related terms and defi-
nitions, depending upon the context and the field. “Survival” is
most commonly used as an epidemiological construct denoting
a period of time between an event and a “failure.” The medi-
cal community considers survival to be the length of time from
medical intervention (e.g., coronary artery bypass surgery, stent
placement, initiation of aspirin) to an event such as death (i.e.,
failure). The primary medical goal is to evaluate effectiveness
in the prevention of mortality, and this model implies that the
disease state is known or diagnosed. Mullan (1985) states that
people become survivors at the time they are diagnosed with a
life-threatening disease. In a New England Journal of Medicine
essay, he explained, “Survival . . . begins at the point of diag-
nosis because that is the time when cancer patients are forced
to confront their own mortality and begin to make adjustments
that will be part of their immediate, and to some extent, long-
term future” (Mullan, 1985, 271). Survivor- “ship” implies that
a trait or attribute is possessed related to survival, such as in
the case of cancer survivors exhibiting strength and perseverance
throughout their treatment and in the confrontation of death
(Zebrack, 2000). While the term “survivorship” most often has
a psychosocial connotation of sustaining life during hardship, we
hypothesize that biologic robustness can be a trait favoring sur-
vival even in the context of complex diseases such as coronary
disease.
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The gerontology literature refers to survivorship as lifespan
longevity irrespective of health indices (Murabito et al., 2012);
and, many researchers in aging consider longevity to be healthy
survival to old age. Centenarians are exemplars of longevity, but
some data suggest that nearly one-third of centenarians have had
age-related morbidities for 15 or more years (Terry et al., 2008),
making at least some of those survivors apparently robust to the
effects of pathophysiologic insults—perhaps due to some bio-
logical advantages. Some researchers have begun to explore the
hypothesis that centenarians are genetically predisposed to phys-
iological states that are protective against heart disease (Grimaldi
et al., 2006) and other conditions, perhaps via “buffered disease
genes” that promote longevity by “buffering” genetically deter-
mined age-related diseases (Bergman et al., 2007). However, these
people are different from those with known coronary disease who
survive despite their disease, who may potentially embody dis-
tinct genetic characteristics. These caveats lead us to make an
important distinction about defining the construct of survivor-
ship in CAD. Timing and context are everything. We present
a model (Figure 1) that accounts for temporal, clinical, and
genetic interrelationships that characterize survivorship in CAD.
In our goal to determine an optimal definition for survivorship
in CAD and determine the plausibility of genetic contribution
to this phenotype, we considered the interplay of these factors.
We present a theory-based definition for survivorship in CAD as
a survival advantage concurrent with clinically significant CAD
and propose an optimal measurement of this phenotype as the
time at initial biological atherosclerotic disease onset to time of
coronary-related death. We discuss the caveats of observing and
measuring the phenotype as recommended and offer alternatives
for approximating the construct of survivorship in CAD through
the use of overlapping phenotypes. We hypothesize that genes
may contribute to the survivorship in CAD phenotype.
THE HYPOTHESIS OF GENETIC CONTRIBUTION TO SURVIVORSHIP
IN CAD
The natural history of CAD makes elucidating genetic con-
tributions to “survivorship” a complex challenge. Our model
(Figure 1) helps to illustrate the interplay of these factors in
generating our hypothesis. Survivorship in CAD is only one
of a number of related and overlapping CAD phenotypes.
Genetic contributions to these overlapping phenotypes suggest
FIGURE 1 | Model for survivorship in CAD depicting temporal
relationships with clinical constructs. Asterisks indicate established
genetic effects in the literature.
that there may be shared genetic markers for survivorship in
CAD. Moreover, there could be different but correlated genetic
effects at each stage, reflected by genetic heterogeneity and/or
differential magnitudes of genetic effect across the time-disease
continuum. Recent findings identify genetic associations with risk
variants in cardiovascular-related mortality and sudden cardiac
death (see extensive review by Arking and Sotoodehnia, 2012).
However, the survivorship in CAD phenotype hinges on the
distinction between determining risk for CAD-related mortality
events vs. characterizing the propensity to survive beyond clin-
ical expectation with significant CAD (as in, cardioprotection).
The key is being able to parse out the proportion of overlap-
ping genetic variance that contributes specifically to survivorship
in the context of CAD. To lend additional support for hypothe-
sized genetic involvement in the survivorship in CAD phenotype,
we look to genetic variants associated with known cardiopro-
tection phenotypes—both in-vitro and limited in-vivo evidence,
reviewed later in the paper.
Genetic heterogeneity likely drives marked inter-individual
variation in disease initiation, progression, and response to treat-
ment, thus, is likely to affect survival likelihood. Naghavi and
SHAPE task force members (Naghavi et al., 2006) provide insight
into the variability therein: “At every level of risk factor exposure,
the amount of established atherosclerosis and the vulnerability of
actual events varies greatly, probably because of genetic variability
in an individual’s susceptibility to atherosclerosis and propen-
sity to arterial thrombosis (“vulnerable blood”) and ventricular
arrhythmias (“vulnerable myocardium”)”, (Naghavi et al., 2006,
4H). Coupled with great variance in modifiable risk factor pro-
files, the task of finding biological variants and/or biomarkers
that pinpoint the initiation of CAD is a daunting one. The fol-
lowing are necessary for accurately defining the origin of CAD
in the study of this novel phenotype: (1) a consensus for what
constitutes “the” biological/biochemical initiation of CAD; (2) a
sensitive and reliable biomarker for that initial biological disease
state; and, (3) evidence that the particular biomarker(s) inde-
pendently predict development of clinically appreciable CAD. In
estimating the earliest known point of origin for disease initiation
(i.e., implications 1 and 2), the epidemiological tenets of what
is “detectable” in the preclinical phase of disease are currently
being challenged by scientific advances, which could make future
research for their prediction of the development of CAD (and sur-
vivorship in CAD) more viable. We next present a review of the
evidence for genetic involvement in each of the presented phases
in our model and reflect on the impact of temporal contexts of
the CAD continuum to the study of the genetics of survivorship
in CAD.
THE TEMPORAL STAGES OF BIOLOGY AND DISEASE: IDENTIFYING THE
SURVIVORSHIP IN CAD POINT OF ORIGIN
Our lifespans are a complex continuum of biological and envi-
ronmental interactions that result in various stages of wellness
and decline (and/or disease). In Figure 1, the lifespan stages are
depicted by the top horizontal line progressing from birth to
death. Disease progression is also by nature a temporal process
with multiple clinical stages, represented here by the middle hor-
izontal lines. Specific to CAD, the major clinical stages can be
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considered: development of risk factors/preclinical disease, symp-
tomatic stage with/without diagnosis and/or coronary event(s);
treatment/maintenance, and death. Inter-individual variance in
disease presentation and the heterogeneous nature of CAD affect
the onset and length of these stages, and, inherently the way
that CAD phenotypes are defined and studied. Given afore-
mentioned definitions, “survivorship in CAD” could simply be
defined as survival time from point of diagnosis to death. While
this definition suits investigations of medical treatment, genetic
investigations seeking to identify markers associated with survival
as a function of biologic protection from CAD-related mortal-
ity should consider an alternate definition, specifically, beginning
with a better and earlier point of origin.
The time point at which we define the origin of the survival
curve is critical. In survival analyses, the origin refers to the nat-
ural point in time in which the person becomes “at risk.” If CAD
diagnosis were used as the origin for the survivorship in CAD
phenotype, this would be an inaccurate assessment because the
pre-clinical phase of CAD also corresponds to a period where risk
for death from CAD is known. Specifically, it is estimated that
the initial presentation of CAD is sudden cardiac death (SCD)
for at least 20–30% of cases (Myerburg and Junttila, 2012; Roger
et al., 2012). SCD cases demonstrate risk of death from asymp-
tomatic CAD during the pre-clinical/pre-diagnosis phase and
there is evidence of genetic variants associated with the risk for
CAD-associated sudden death (Westaway et al., 2011). Therefore,
the optimal origin for defining the survivorship in CAD pheno-
type should be the initial biological disease state, which we know
occurs before the diagnosis of CAD. Methodologically, this is cur-
rently problematic. We cannot “carbon-date” the exact onset of
disease, given the potentially long period of pre-clinical, asymp-
tomatic phase associated with CAD. Current proxies are tradi-
tional biomarkers, such as coronary artery calcium (CAC) scores,
C-reactive protein (CRP), and carotid intima media thickness
(CIMT), discussed later.
DEVELOPMENT OF RISK FACTORS/PRE-CLINICAL DISEASE
Development of risk factors and pre-clinical disease overlaps
with our defined phase of survivorship in CAD and likely
shares genetic contributions to this phenotype. Here, we con-
sider both traditional (age, diabetes, smoking, hypertension, dys-
lipidemia, obesity, and family history of early-onset CAD) and
non-traditional risk factors. The multitude of non-traditional
risk factors include, for example, CRP, homocysteine, fibrinogen,
lipoprotein a, calcium score, metabolic syndrome, renal disease,
and microproteinuria. Evidence of genetic contribution to these
well-studied risk factors has been established and summarized
extensively in the literature to date.
For any disease, the pre-clinical phase is characterized by
three periods: the initiation of biological insult, the un-detectable
pre-clinical state, and the detectable pre-clinical state (Herman
et al., 2002). Pre-clinical coronary disease is characterized by
the development of risk factors and the physiologic initiation of
inflammation and atheroma development. An ideal marker for
approximating the initial biological disease state for survivor-
ship in CAD would be one that had high sensitivity and speci-
ficity for detecting initial endothelial dysfunction (oxidation of
low-density lipoprotein in the arterial wall and/or inflammation
of endothelial cells). Genetic contribution to these broad physio-
logic phases warrants a separate review. Briefly, some strong sub-
clinical CAD biomarker candidates exist for the earliest known
phases of atherosclerotic development (Table 1). Accurate detec-
tion of the earliest initiation of the biophysiologic process of
disease development appears to be on the horizon. The “tradi-
tional” subclinical markers of vascular disease (CRP, CAC, and
CIMT) have evidence of moderate heritability. Heritability esti-
mates for CRP levels is estimated between 26 and 45%, depending
on the population studied (MacGregor et al., 1999; Pankow et al.,
2001; Lange et al., 2006; Fox et al., 2008). The heritability of
quantity of CAC within carotid vessels of asymptomatic white
individuals has been estimated between 38 and 42% (Cassidy-
Bushrow et al., 2007; Rampersaud et al., 2008) after adjustment
for various risk factors. Cassidy-Bushrow et al. (2007) further
demonstrated heritability of progression of CAC across 7 years,
with a post-adjustment estimate of 40%, wherein genetic factors
explained 14% of the variation in CAC progression. The heritabil-
ity of CIMT was first demonstrated in the FraminghamOffspring
cohort, with age- and sex-adjusted estimates of 37–44% (Fox
et al., 2003). Estimates of twin cohorts (Zhao et al., 2008; Lee
et al., 2012) are higher with adjusted h2 of 38–59%, and as much
as 65% (adjusted h2) in Caribbean Hispanic populations (Sacco
et al., 2009).
Pre-clinical disease can begin as early as childhood, espe-
cially where traditional risk factors are present in early ages. The
presence of raised fibrous plaques has been documented in chil-
dren as young as 8 years of age who had type 1 diabetes and
who died from accidental causes in the Bogalusa Heart Study
(Berenson et al., 1998). Other epidemiologic studies of chil-
dren and young adults (Pathobiological Determinants of Youth
Study, Cardiovascular Risk in Young Finns; Coronary Artery Risk
Development in Young Adults) have documented the presence of
coronary and aortic fatty streaks in these populations and cor-
relations between detectable streaks and some traditional risk
factors (McMahan et al., 2006; Loria et al., 2007; Hartiala et al.,
2012). The fact that the biological origin of CAD may begin
so early in life constitutes another layer of complexity in defin-
ing the point of origin for survivorship in CAD; yet, advances
may be leading us to more accurate detection of the initial bio-
physiologic insults leading to CAD, as early as childhood. Given
the potential for emerging biomarkers to characterize the earliest
Table 1 | Sub-clinical CAD biomarkers.
Atherosclerotic phase of
involvement
Biomarkers Review citation
Oxidation of low-density
lipoprotein in the arterial wall
OxLDL, OxPL/ApoB Fraley and Tsimikas,
2006
Inflammation of endothelial
cells
CRP, IL-6, WBC, VCAM-1,
ICAM-1, PLA2
Galkina and Ley, 2007;
Vaccarino et al., 2011
OxLDL, oxidized low-density lipoprotein; OxPL, oxidized phospholipid; ApoB,
apolipoprotein B; CRP, C-reactive protein; IL-6, interleukin-6; WBC, white blood
cells; VCAM-1, vascular cellular adhesion molecule-1; ICAM-1, intracellular
adhesion molecule-1; PLA2, phospholipase A2.
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detectable initiation of atherosclerotic disease (earlier than CRP,
CAC, and CIMT), we assert that the construct of survivorship in
CAD remains best defined as survival from time at initial biologi-
cal atherosclerotic disease onset to time of coronary-related death.
We believe that biomarker advances will allow us to optimally
define earlier points of origin in the near future. If such biomark-
ers (CRC, CAC, CIMT, or novel) are measured in an at-risk,
pre-clinical population, the survivorship in CAD origin could be
the time at biomarker capture (for those with biomarker levels
corresponding to increased risk for CAD). Participants could be
followed from pre-clinical phase to point at conversion to CAD
diagnosis, then until coronary-related death. Capture of genetic
data from this type of cohort would be ideal for investigating the
genetic contribution to survivorship in CAD. Furthermore, one
could test the genetic contributions to each phase or point of sur-
vival along the time-disease-treatment trajectory. This approach
could discriminate whether identified genes are equally important
at each phase or whether there are different genes corresponding
to different effects across this continuum. Until earlier biomarkers
are validated, or until an at-risk cohort (with sufficient data and
power) is prospectively followed as previously described, proxies
for the origin point, such as time of clinical CAD diagnosis, will
be necessary.
SYMPTOMATIC STAGE WITH/WITHOUT CAD DIAGNOSIS
CAD diagnosis is driven by symptomatology. For those whose
initial symptoms are less severe or who survive their initial
atherosclerotic vascular event, numerous candidate genes have
been associated with the presence and diagnosis of CAD. Recently,
Yoo et al. (2012) explored the role of polymorphisms in the
Rho-associated kinase 2 (ROCK-2) gene in vasospastic angina
and found that a 5-marker haplotype conferred protection from
coronary vasospasm in 106 Korean adults undergoing coronary
angiography (p = 0.007). Genetic investigation into CAD symp-
toms is new territory in the literature but the demonstration of
genetic association with vasospasm identifies the potential for
genetic variants to be involved in the predisposition to CAD
symptoms. Age of onset of CAD diagnosis has strong evidence
of genetic contributions to development of CAD, with earlier
age of onset suggesting a stronger genetic effect (Arking et al.,
2003; Hauser et al., 2004; Connelly et al., 2006; Shah et al., 2006,
2009). Estimates of over 2000 known or suspected candidate
genes involved in CAD are present in the literature (IBC 50K
CAD Consortium, 2011). The 9p21 region has the most evidence
established to date for CAD, as the most highly replicated variants
come from the 9p21 region for significant associations with CAD
andmyocardial infarction (Palomaki et al., 2010), and sudden and
arrhythmic cardiac death (Newton-Cheh et al., 2009).
TREATMENT/MAINTENANCE
The treatment and maintenance phase of the CAD continuum
primarily includes interventional cardiology procedures and/or
pharmacological management. Genetic contribution to treat-
ment response in CAD is also well-established, particularly as
the pharmacogenomics revolution has been the fastest pipeline
for translation of genetic screening in the context of complex,
multifactorial diseases. A recent review by Voora and Ginsburg
(2012) summarizes the evidence of genetic associations with the
most common cardiovascular drug classes used in the preven-
tion and treatment of CAD (antiplatelet agents, warfarin, statins,
beta-blockers, diuretics, and antiarrhythmic drugs). Significant
pharmacogenetic associations have been reported for mortality.
This is key to our construct for two reasons: first, cardiovascular
treatment effects and the survivorship in CAD phenotype could
share genetic variation—further supporting our hypothesis; and,
second, there is a likelihood that in situations where non-shared
genetic effects are present for survivorship in CAD, cardiovascular
treatment effects (involving genetic risk or not) may indepen-
dently bias survival models. Similar caveats persist related to
treatment effects from interventional procedures for CAD, such as
with coronary artery bypass grafting (CABG), percutaneous coro-
nary angioplasty (PTCA), and stent placement, for which patients
may also have varied prognoses and outcomes based on certain
genetic markers (Muehlschlegel et al., 2010; Cayla et al., 2011;
Lobato et al., 2011).
DEATH
A landmark analysis of clinician vs. computational prognoses of
survival by Kong and colleagues (Kong et al., 1989) indicated that
clinically, we are poor at predicting survival in CAD; and, that
accurate estimation of survival outcomes is difficult. Over 20 years
later, strong evidence has been found implicating the following as
independent predictors of death in CAD: age, race (Thomas et al.,
2010), presence of comorbidities (diabetes/metabolic syndrome),
renal disease, hypertension (Emerging Risk Factors Collaboration
et al., 2010), depression (Whang et al., 2010), and reduced ejec-
tion fraction (Movahed and Sattur, 2010; Kuhl et al., 2011). In
those at-risk or diagnosed with CAD, the use of aspirin, beta-
blockers, ACE-inhibitors, and statins can significantly reduce the
risk of death by 15–50%; early reperfusion can reduce mortality
by 25–30%.
Genetic factors may provide further insight into mortality
risk. Evidence for genetic involvement in mortality phenotypes
such as in sudden cardiac death (Arking and Sotoodehnia, 2012),
acute coronary syndrome (Xu et al., 2013), and all-cause mor-
tality post-acute coronary syndrome (Morgan et al., 2008, 2011)
has been modestly demonstrated. Aouizerat et al. (2011) con-
ducted a GWAS of sudden cardiac death in patients with CAD and
reported 11 significant gene associations for six novel candidates
and validated eight known variants for this phenotype. Johnson
and colleagues (Johnson et al., 2012) have identifiedmultiple fatty
acid gene variants associated with survival to admission and sur-
vival to discharge in out-of-hospital sudden cardiac death. The
relationship between SCD and survivorship is testable. If there is
a risk allele for SCD, we could expect the frequency of that allele
to be lower in survivors of CAD.
CAVEAT: CARDIOPROTECTIVE GENES
Given our distinction regarding survivorship in CAD as the
propensity to survive beyond clinical expectation with signifi-
cant CAD, it is logical that the focus of finding unique genetic
variants for survivorship could be on cardioprotective genetic
variants rather than cardiovascular risk markers. It is also impor-
tant to consider the potential for heterozygous advantage for
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survival conferred by some risk variants for these overlapping
constructs, as in the example of malaria and sickle cell disease.
Some promising data exist on cardioprotective genes, but the
majority of the science in this area is limited to animal models and
in-vitro studies of cellular survival of cardiac cells and/or preven-
tion of apoptosis (Zhang et al., 2009; Weng et al., 2010). Innate
cardioprotective phenotypes include ischemic preconditioning,
hypoxic preconditioning, and heat shock preconditioning. Work
in this area has uncovered some promising candidate genes,
most prominently the nuclear factor kappa-B (NFKB) (Wilhide
et al., 2011) and related heat shock protein (HSP) genes, necessary
mediators of cardioprotective mechanisms following ischemic
preconditioning (Tranter et al., 2010). Micro-RNAs are hypoth-
esized to be involved in cardioprotection due to their ability to
regulate processes involved in cardiac injury and protection (see
review by Kukreja et al., 2011). While other biomarkers have been
implicated in preconditioning phenotypes [hypoxia inducible
factor-1 (HIF-1; Tekin et al., 2010; Ong and Hausenloy, 2012);
tissue kallikrein (TK; Messadi-Laribi et al., 2008); erythropoietin,
heme oxygenase-1, and inducible nitric oxide synthase (Ong and
Hausenloy, 2012), paroxonase, clusterin, and apolipoprotein A-1
[(MacKness et al., 1997)], there is limited evidence for genetic
involvement in cardioprotection.
Population-based studies have identified some candidate genes
significantly associated with protection against incident CAD,
but have failed to produce candidate genes for survival in CAD.
Briefly, A single nucleotide polymorphism (rs3217989) corre-
sponding to cyclin-dependent kinase inhibitor-2B (CDKN2B) in
the 9p21 region was protective against incident CAD in a sample
of 548 African Americans [OR = 0.19, 95% CI = 0.07–0.50, p =
0.0008, a finding that was further replicated in a larger combined
sample of 990 African Americans (Kral et al., 2011)]. The ADA∗2
allele in the adenosine deaminase (ADA) gene was hypothesized
by Safranow et al. (2007) to modulate cardioprotection via its
indirect effects on levels of adenosine—a potent cardioprotective
agent. They reported lower frequencies of the ADA∗2 gene variant
in CAD-diagnosed individuals in a sample of 371 Poles (Safranow
et al., 2007).
ALTERNATIVE HYPOTHESES
We hypothesize that genes could play a unique role in the ability
to survive in the context of clinically significant coronary dis-
ease. Genetic principals that offer support for survival traits in
the context of unfavored phenotypes are heterozygous advan-
tage and antagonistic pleiotropy. For example, evaluation of the
Framingham Heart Study revealed that APOE gene variants were
associated with survival-related pleiotropic effects in cancer and
age of onset of CAD (Kulminski et al., 2011). An alternative
hypothesis is that there is no genetic involvement in coronary
disease-related survival. As we have presented earlier, up to one-
third of centenarians have age-related morbidities (such as heart
disease) for 15 or more years (Terry et al., 2008). Furthermore, we
have presented evidence of genetic contribution to overlapping
phenotypes with survivorship in CAD and hypothesize shared
genetic variance among these phenotypes. Other non-genetic
factors could contribute more significantly to survival (such as
treatment effects) that may mask or override any genetic effects
contributing to survivorship in CAD. Observations of greater
survival in the context of CAD could be also be due to a popu-
lation effect in which a select group (or family) has a tendency for
longer survival in spite of the presence of CAD (theoretically, as
in family-based centenarians from Mediterranean areas).
PILOT EVIDENCE OF SURVIVAL-VARIANT GENES IN CAD
USING A PROXY DEFINITION FOR SURVIVORSHIP IN CAD
As we are unaware of a cohort for which pre-clinical biomarkers
and genetic data have been captured for at-risk, asymptomatic
people prospectively followed through development of CAD
that has adequately powered mortality rates, we set out to
generate at least preliminary evidence of genetic variation in
survival likelihood for symptomatic CAD-diagnosed people.
We performed a secondary analysis of 1885 subjects from a
primary case-control genetics study of symptomatic patients
undergoing cardiac catheterization (Catheterization Genetics
Study; CATHGEN), described elsewhere (Sutton et al., 2008).
Briefly, the primary study recruited patients presenting to the
cardiac catheterization lab (regardless of disease status) for a
cardiovascular genetics study and biorepository in which medical
history, clinical data, and biological samples were collected.
Biological data were stored in the Center for Human Genetics
facility; all other data were stored in the Duke Databank for
Cardiovascular Disease and maintained at the Duke Clinical
Research Institute (Fortin et al., 1995). Both the primary and
secondary studies obtained approval from the Duke University
Medical Center Institutional Review Board. All participants
provided informed consent for participation. Our specific aim
for the secondary analysis was to evaluate whether the likelihood
of survival was significantly different among candidate genes for
cases with angiographically-defined, clinically significant CAD.
For this case-only analysis, we evaluated 34 previously genotyped
single nucleotide polymorphisms (SNPs; Table 2), representing
five a priori CAD candidate genes of interest from the primary
CATHGEN study. The candidate genes for our secondary
analyses were either previously associated with age-related CAD
phenotypes or were highly suspect of having survival effects,
based on published findings from our group [ALOX5AP (Shah
et al., 2008; Crosslin et al., 2009), FAM5C (Connelly et al.,
2006), KALRN (Wang et al., 2007), LSAMP (Wang et al., 2008),
PLA2G7 (Sutton et al., 2008)]. Genomic DNA for CATHGENwas
extracted from whole blood using the Puregene system (Gentra
Systems, Minneapolis, MN, USA). Genotyping was performed
at the Duke Center for Human Genetics genotyping laboratory
(Durham, NC, USA). The primary study originally selected SNPs
in 2004 based on reported literature for CAD and age-related
CAD candidate genes, and from a list of age-related CAD
candidate SNPs in the GENECARD family study of early-onset
CAD (Hauser et al., 2004). Additional follow-up SNPs in these
candidate genes were later selected based on the aims of ancillary
studies and/or availability of the SNPs for these candidate genes
on selected genotyping platforms. Three different genotyping
platforms were used in the primary study: TaqMan 7900 HT
(Applied Biosystems, New York, USA); Illumina HumanOmni1-
Quad_v1-0_C chip; and, custom Illumina GoldenGate Bead
Arrays (San Diego, CA, USA). The 384-well plates included a
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Table 2 | SNPs.
Gene SNPs
ALOX5AP rs3803277, rs4147064, rs9506352
FAM5C rs12076854, rs2990996, rs1442569, rs16832305, rs1272400
KALRN rs7616435, rs627830, rs9289235, rs7623685, rs2289843,
rs1867647, rs2289420
LSAMP rs9822311, rs10511352, rs6776244, rs1870709, rs9847048,
rs1518898, rs6788787, rs1915585, rs1462845, rs4356827,
rs1354152, rs1698041, rs2937673, rs1676232, rs1381801,
rs4404477, rs4687889
PLA2G7 rs1421378, rs1862008
ALOX5AP, arachidonate 5-lipoxygenase-activating protein; FAM5C, family with
sequence similarity 5, member C; KALRN, kalirin; LSAMP, limbic system-
associated membrane protein; PLA2G7, phospholipase A2; group VII (platelet-
activating factor acetylhydrolase, plasma).
total of 20 quality control samples (eight CEPH (Center d’Étude
du Polymorphisme Humain) pedigree individuals, eight study
sample duplicates, and four no-template controls). SNP mis-
matches were reviewed by an independent genotyping supervisor
for potential genotyping errors. Each SNP had a call frequency
across all individuals of at least 95%; each individual had a call
rate across all SNPs of at least 95%. For the TaqMan platform,
blinded duplicate samples were used to determine the error
rates, which were <0.2% among SNPs that passed genotyping
quality control. For the secondary analysis, we selected SNPs
for these candidate genes that met our quality control metrics
and that were also genotyped at that time in the Framingham
Heart Study (as we were anticipating replication analyses in that
dataset), leaving the 34 SNPs in Table 2 for this secondary pilot
analysis. All SNPs met our established criteria (Shah et al., 2009;
Zhang et al., 2010) for quality control (QC) Hardy-Weinberg
equilibrium (HWE) and linkage disequilibrium (LD).
Statistical analyses were performed using the R program’s
Survival package (R Development Core Team, 2008). Means and
frequencies were calculated for demographic variables, diagnosis,
and events. The survivorship in CAD phenotype was defined in
this analysis as time from angiographically-defined CAD case sta-
tus in symptomatic individuals to time at all-cause mortality. The
primary study did not recruit asymptomatic patients with CRP,
CAC, or CIMT data to serve as an optimal point of origin for
evaluation of survivorship in CAD. We considered the alternative
analytical approach in which we would identify a subset of control
subjects that converted to CAD diagnosis (to use as a proxy for the
pre-symptomatic point of origin); however, only two participants
would have met the criteria for the analyses. More importantly,
by our recommendation, CRP, CAC, and CIMT levels would be
ideal for verifying the increased risk for CAD in these “convert-
ers,” but these labs are not routinely ordered on patients that meet
“control” status after cardiac catheterization. An excess of missing
data for the cause of death variable precluded our use of the ideal
phenotype endpoint of coronary-related death. Therefore, we
used time from cardiac catheterization to all-cause mortality as
a proxy definition. In order to determine if there were significant
genetic effects on survival in the context of CAD but not in con-
trols, we performed analyses stratified by CAD case status. Thus,
Cox proportional hazards models estimated instantaneous risk
[hazard ratio and 95% confidence interval (CI)] of all-cause mor-
tality by genotype groups separately in CAD cases and controls
censored on number of days from study enrollment (time at coro-
nary catheterization) to all-cause death or last follow-up. Survival
curves for long-term survival were illustrated using Kaplan-Meier
curves. Cases were defined as having at least one major epicar-
dial vessel having at least 75% stenosis on coronary angiography
(Duke CAD index > 23) (Sutton et al., 2008). Controls were
defined as having no appreciable CAD (Duke CAD index < 23),
corresponding to angiographic data indicating no more than one
major epicardial vessel having less than or equal to 75% occlusion
as demonstrated by coronary angiography, and no documented
history of cerebrovascular or peripheral vascular disease, myocar-
dial infarction, transplant, or interventional or surgical coronary
revascularization procedures (Sutton et al., 2008). An additive
inheritance model was assumed, assigning wild-type genotypes a
value of 0, heterozygous genotypes a value of 1, and risk homozy-
gous genotypes a value of 2. All SNPs were analyzed separately
with a basic model evaluating only the main effect of genotype
and a separate covariate model controlling for age, sex, body mass
index (BMI), and histories of smoking, type 2 diabetes, hyperlipi-
demia and hypertension. As a post-hoc analysis for the case-only
group, we added CAD index as a covariate in the full clinical
covariate model in order to determine if the significant survival
effects were impacted by disease severity. In addition, we evalu-
ated the impact of sex on the survival results using a stratified Cox
proportional hazards analyses in CAD cases, controlling for age,
bodymass index (BMI), and histories of smoking, type 2 diabetes,
hyperlipidemia and hypertension.
For this pilot analysis, 1885 subjects with genetic data meet-
ing standard quality control metrics were analyzed. Demographic
and cohort characteristics are presented in Table 3. Four hundred
subjects (21.2%) were deceased on follow-up at the time of anal-
ysis; 1155 subjects met our criteria for CAD diagnosis with an
event rate of 21.9% (n = 253) and 730 were considered controls,
with an event rate of 20.1% (n = 147). Vital events were con-
firmed through the National Death Index, as previously described
(Shah et al., 2010). As expected, CAD cases who experienced
events tended to be older, had a greater burden of disease (higher
CAD index), lower BMI, and a higher frequency of hypertension.
Deceased CAD cases also had a lower frequency of hyperlipi-
demia, demonstrating a paradoxical phenomenon between mor-
tality and hyperlipidemia, previously reported by our group and
likely due to treatment effects or confounders (Wang et al., 2009;
Shah et al., 2012). Deceased participants with CAD also had a
reduced frequency of smoking compared to living CAD cases,
which may be explained by the self-report measurement of his-
tory of smoking and/or the option to report having ever smoked
or currently smoking as positive history vs. not currently smoking
as negative history. Racial representation varied little by event and
diagnosis groups.
Based on a follow-up of 2738 days (about 7 years, 5 months),
three SNPs (rs1462845, rs1915585, and rs6788787) in the LSAMP
gene had significant hazards of death in CAD cases (Table 4,
uncorrected p-values), but differed in their gene dosing pat-
terns and directions of effect. Data for these three SNPs met the
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Table 3 | CATHGEN demographic and clinical characteristics.
Characteristic All (N = 1885) All subjects (N = 1885) CAD cases (N = 1155)
Alive (n = 1485) Dead (n = 400) Alive (n = 902) Dead (n = 253)
Age, x¯ ± SD, (range) 62.8 ± 13.0 (20–93) 61.3 ± 12.6 (24–91) 68.4 ± 12.9 (20–93) 59.1 ± 12.8 (27–90) 67.6 ± 13.1 (34–91)
CAD index, x¯ ± SD 41.4 ± 31.3 40.0 ± 30.9 47.0 ± 32.3 59.9 ± 21.5 66.7 ± 21.2
Male, no (%) 1210 (64.2) 946 (63.7) 264 (66) 667 (74) 183 (72.3)
Race, no (%)
White 1409 (75.0) 1104 (74.3) 305 (76.3) 683 (75.7) 198 (78.3)
Black/AA 338 (18.0) 270 (18.2) 68 (17) 159 (17.6) 38 (15.0)
Other 138 (7.0) 111 (7.5) 27 (6.7) 59 (6.7) 17 (6.7)
Body mass index, x¯ ± SD 29.5 ± 6.6 29.9 ± 6.6 28.4 ± 6.4 30.0 ± 6.6 28.7 ± 5.8
Smoking, no (%) 1013 (53.8) 796 (53.6) 217 (54.3) 555 (61.5) 143 (56.5)
Dyslipidemia, no (%) 1173 (62.2) 931 (62.7) 242 (60.5) 650 (72.1) 177 (70.0)
Hypertension, no (%) 1322 (70.1) 1022 (68.8) 300 (75) 634 (70.3) 204 (81)
CAD, coronary artery disease; SD, standard deviation; AA, African American.
Table 4 | Cox proportional hazards by SNP for CAD cases and controls.
SNP MA
(MAF)
CAD cases (G)
HR (95% CI)
Controls (G)
HR (95% CI)
CAD cases (C)
HR (95% CI)
Controls (C)
HR (95% CI)
rs1462845 G (0.15) 1.24 (1.00–1.54)* 1.26 (0.89–1.79) 1.26 (1.02–1.57)* 1.10 (0.76–1.59)
rs1915585 T (0.39) 0.70 (0.49–0.99)* 0.99 (0.57–1.70) 0.64 (0.45–0.91)* 1.04 (0.59–1.84)
rs6788787 A (0.15) 0.70* (0.50–0.98)* 0.99 (0.57–1.70) 0.68 (0.49–0.94)* 1.22 (0.70–2.15)
SNP, single nucleotide polymorphism; MA, minor allele; MAF, minor allele frequency; (G), main genotype model; (C), covariate model; HR, hazard ratio; CI, confidence
interval;*p < 0.05.
Table 5 | Genotype frequencies by sample and case status.
Sample rs1462845 rs1915585 rs6788787
AA AA GG GG GT TT GG GA AA
Full (N = 1885) 0.38 0.46 0.16 0.71 0.27 0.02 0.72 0.26 0.02
CAD Cases (n = 1155) 0.39 0.46 0.15 0.73 0.25 0.02 0.72 0.25 0.03
Controls (n = 730) 0.37 0.44 0.19 0.71 0.28 0.01 0.71 0.28 0.01
Risk homozygous genotype frequencies indicated in bold.
assumption of proportional hazards (data not shown). Minor
allele frequencies are presented in Table 4 and genotype frequen-
cies by sample and case status are presented in Table 5. For the
rs1462845 SNP, the risk of death for CAD cases was 1.24 times
greater for each addition of the minor (risk) allele compared to
wild-type genotype (p = 0.044). For rs1915585 and rs6788787,
the hazard ratios are less than one (with significant p-values;
p = 0.044 and 0.037, respectively), suggesting that the minor alle-
les may have a significant protective effect against risk of death in
CAD. The genotype effects on survival remained significant when
controlling for known CAD risk factors (Table 4). In order to
determine whether the survival effects for genotype were specif-
ically driven by CAD, we then performed previously described
survival analyses in control subjects. None of the control subjects
had significant gene effects on survival in either model, suggesting
the genotype effects on survival may be unique to CAD.
Evaluating the Kaplan-Meier (K-M) survival curves for CAD
cases revealed an expected gene dosing pattern for rs1462845
(Figure 2). In an additive genetic model of survival, we would
expect to see a gene-dosing phenomenon, whereby having two
copies of the risk allele (risk homozygous genotype) confers the
worst survival, having no copies of the risk allele (wild-type
homozygous genotype) confers the best survival, and having one
copy of each (heterozygous genotype) falls between the two.
For rs1915585 (Figure 3) and rs6788787 (Figure 4), K-M curves
revealed that subjects with the heterozygous genotype (blue line)
conferred better survival than those with the wild-type geno-
type, which explains the hazard ratios of less than 1 for these
SNPs. These results could be due to the low frequency of risk
homozygous carriers for the rs1915585 and rs6788787 variants in
our sample, the result of insufficient power or rare homozygos-
ity (see Table 5). Another possible explanation for observing this
phenomenon is heterozygous advantage. Heterozygous advantage
(or, hybrid vigor) can be the result of dominance or overdomi-
nance in the population, which acts to selectively advantage the
heterozygous individual in spite of the presence of a single copy
of the risk allele. These SNPs do not have documented evidence
of hybrid vigor at this time. Other possible explanations for this
inappropriate gene-dosing could be antagonistic pleiotropy or
survival bias. Others have simulated erosion of genetic associa-
tions for highly lethal diseases (such as myocardial infarction)
due to culling of risk variants from the population (Anderson
et al., 2011). As aforementioned, longitudinal data would allow
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FIGURE 2 | Kaplan–Meier survival curves for CAD cases vs. controls in
additive (genotype) model for LSAMP SNP rs1462845. X -axis displays
the number of days from index catheterization to death (all-cause mortality).
Y -axis displays the Kaplan-Meier survival probability by genotype. G is the
minor allele; AA, wild-type genotype (reference; black curve); AG,
heterozygous genotype (blue curve); and GG, risk homozygous genotype
(red curve).
FIGURE 3 | Kaplan-Meier survival curves for CAD cases vs. controls in
additive (genotype) model for LSAMP SNP rs1915585. X -axis displays
the number of days from index catheterization to death (all-cause mortality).
Y -axis displays the Kaplan-Meier survival probability by genotype. T is the
minor allele; GG, wild-type genotype (reference, black curve); GT,
heterozygous genotype (blue curve); and TT, risk homozygous genotype
(red curve).
for evaluation of whether the surviorship in CAD effects are due
to genetic factors or are observed as a result of survival bias. It is
important to note that traditional survival bias would be consid-
ered a loss of genetic information due to mortality events in the
data; yet, we are interested in characterizing a genetically-driven
net survival advantage in the context of CAD.While our pilot data
are not designed to show exact proof of the latter concept, our
results do lend preliminary support for genetic differences in sur-
vival unique to symptomatic CAD, adding to the theoretical basis
for genetic involvment in the survivorship in CAD phenotype.
FIGURE 4 | Kaplan–Meier survival curves for CAD cases vs. controls in
additive (genotype) model for LSAMP SNP rs6788787. X -axis displays
the number of days from catheterization to death (all-cause mortality).
Y -axis displays the Kaplan–Meier survival probability by genotype. A is the
minor allele; GG, wild-type genotype (reference; black curve); GA,
heterozygous genotype; and AA, risk homozygous genotype (red curve).
FIGURE 5 | Kaplan–Meier survival curves for CAD cases vs. controls in
dominant (allele) model for LSAMP SNP rs1462845. X -axis displays the
number of days from index catheterization to death (all-cause mortality).
Y -axis displays the Kaplan–Meier survival probability by genotype. G is the
minor allele; AA, wild-type genotype (reference; black curve), and red curve
indicates AG and GG genotypes combined.
Furthermore, when examining the dominant model, (a com-
mon approach to improve power to detect an association when
the minor allele frequency is low), the K-M curve for rs1462845
showed expected curves, wherein having any copy of the minor
(risk) allele confers worse survival compared to the wild-type
genotype (Figure 5). However, combining risk genotypes in the
dominant model for the rs6788787 SNP (Figure 6, red line)
results in a survival curve that suggests the minor (risk) allele
confers better survival in the presence of CAD. Theoretically,
this could drive unexpected or spurious results in an associa-
tion between the LSAMP SNP and CAD if survival effects were
not considered. The SNP rs1915585 (Figure 7) showed a trend
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FIGURE 6 | Kaplan–Meier survival curves for CAD cases vs. controls in
dominant (allele) model for LSAMP SNP rs6788787. X -axis displays the
number of days from catheterization to death (all-cause mortality). Y -axis
displays the Kaplan-Meier survival probability by genotype. A is the minor
allele; GG, wild-type genotype (reference; black curve); and red curve
indicates GA and AA genotypes combined.
similar to rs6788787 for both additive and dominant models. To
determine if the significant survival effects by genotype were due
to the severity of CAD, we then performed the case-only Cox
model, adding CAD index as a term in the full covariate model.
The genotype effect remained significant for all three SNPs when
controlling for disease severity (p = 0.03 for rs1462845, p = 0.01
for rs1915585, and p = 0.01 for rs6788787). CAD index itself
was only marginally significant as a predictor of survival in this
model (p = 0.07 for rs1462845 and rs1915585 and p = 0.04 for
rs6788787). As sex differences are established in CAD and CAD-
related mortality, we also evaluated Kaplan–Meier curves and Cox
models for CAD cases stratified by sex, controlling for age, body
mass index (BMI), and histories of smoking, type 2 diabetes,
hyperlipidemia, and hypertension. All three SNPs had signifi-
cant genotype effects in male CAD diagnosed subjects (n = 850)
but not female CAD diagnosed subjects (n = 305; Supplemental
Table 1). The rs1462845 survival curves (Supplemental Figure 1)
demonstrated genotype-specific effects in males comparable to
the full dataset and no appreciable genotype-specific pattern
on survival in females. For the rs1915585 and rs6788787 SNPs
(Supplemental Figures 2, 3), genotype-specific survival patterns
for males and females were consistent with the full sample model
(e.g., consistent heterozygous advantage effects), but conclusions
about these effects cannot be drawn due to the reduced power
in this sex-based analyses and reduced homozygosity similar to
the full CAD case models (Supplemental Table 1). These results
suggest sex-specific genotype effects on survival in symptomatic,
CAD-diagnosed individuals for the rs1462845 SNPs and possible
sex differences for other LSAMP SNPs; however, a larger sample
size is necessary to confirm this relationship.
In summary, three LSAMP SNPs show significant differences
in survival by genotype in CAD cases but not controls, even
after adjusting for age, sex, body mass index (BMI), and histories
of smoking, type 2 diabetes, hyperlipidemia, hypertension, and
FIGURE 7 | Kaplan–Meier survival curves for CAD cases vs. controls in
dominant (allele) model for LSAMP SNP rs1915585. X -axis displays the
number of days from index catheterization to death (all-cause mortality).
Y -axis displays the Kaplan-Meier survival probability by genotype. T is the
minor allele; GG, wild-type genotype (reference; black curve); and red curve
indicates GT and TT genotypes combined.
disease severity. Sex-stratified analyses revealed that these effects
were unique tomales. This work provides preliminary evidence of
gene-related survival effects unique to CAD. The limbic system-
associated membrane protein (LSAMP) gene is a 64–68 kD gene
located on the long arm of chromosome 3. It encodes a neu-
ronal surface glycoprotein [OnlineMendelian Inheritance inMan
(OMIM), 2011] and has been described as a tumor suppres-
sor gene that may be fundamental to brain development (Wang
et al., 2008). Our group has previously found multiple LSAMP
SNPs to be significantly associated with late age of onset CAD
(diagnosis in males ≥51 years of age, females ≥56 years of age),
some of which had stronger genetic effects in individuals with
severe CAD, i.e., the presence of left main coronary disease (Wang
et al., 2008), further supporting LSAMP’s candidacy for CAD-
specific survival effects. The rs6788787 and rs1915585 SNPs were
previously reported to be in strong linkage disequilibrium in
CATHGEN [pairwise r-square = 0.74 (Wang et al., 2008)], how-
ever, our subset sample data do not support LD between these two
markers (all pairwise correlations less than 60%).
CONCLUSION
Every minute, someone dies of coronary disease in America
(Roger et al., 2011). The ratio of deaths per year to incident cases
of stable angina is roughly equal (∼400,000:500,000) (Roger et al.,
2011). Investigating genetic contributions to improved survivor-
ship with CAD could provide unique insights for better health
promotion and prognosis. Identifying genetic variants associated
with improved survivorship in CAD could lead to improved clin-
ical prediction and insights into biological mechanisms critical to
the complex disease-survival interface. Knowledge of such vari-
ants could also support a shift in focus from preventing death to
promoting optimal conditions for survival in concert with known
genetic makeup. Measurement of the optimal phenotype interval,
consideration for shared and non-shared genetic effects with
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overlapping constructs, and interplay with treatment effects in
this process will be critical components of such investigations.
We hypothesize genetic contribution to this phenotype based
on our model depicting shared genetic variation with related
and overlapping constructs. We further support the concept of a
genetic basis for survivorship in CAD with preliminary evidence
of genetic differences in survival in CAD for certain LSAMP SNPs.
This model can help generate hypotheses about the genetic archi-
tecture of survivorship in CAD and support appropriate measure-
ment. Future work can address important questions about genetic
and other factors involved in CAD-specificmortality and survival,
which may help improve clinical prediction of survival and mor-
tality in people with CAD. This could lead to further insight into
the biological and/or functional mechanisms of survivorship in
CAD. Finally, refining the genetic factors for survivorship in CAD
may lead to improvement in the signal-to-noise ratio in genetic
associations with CAD as well as for replications.
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